Background
==========

Visceral leishmaniasis (VL) is a debilitating vector borne disease caused by parasites of the *Leishmania donovani*complex. Prevalence is high in Bihar State in India, indicating a need to understand more about disease pathogenesis to facilitate disease control. Population based epidemiological surveys suggest that 80-90% of individuals infected with *L. donovani*show no clinical symptoms \[[@B1],[@B2]\]. Familial clustering, and the range of clinical outcomes from asymptomatic to fatal disease within and between ethnic groups sharing similar risk factors in Brazil \[[@B3],[@B4]\] and Sudan \[[@B5],[@B6]\], support a contribution of host genotype to susceptibility. Candidate gene and genome-wide linkage studies have highlighted a number of genes/gene regions contributing to disease susceptibility (reviewed \[[@B7]\]). However, replication between study sites has not been observed possibly due to small samples size and limited statistical power.

Amongst the genes studied to date, the most compelling candidate for VL susceptibility is *SLC11A1*(formerly *NRAMP1*). *SLC11A1*encodes solute carrier family 11a member 1, a transporter that regulates divalent cation homeostasis in macrophages and has many pleiotropic effects on macrophage activation (reviewed \[[@B8],[@B9]\]). The gene was first identified for its role in controlling *Leishmania donovani*(gene designation *Lsh*), *Salmonella typhimurium*(*Ity*) and *Mycobacterium bov*is (*Bcg*) infections in mice \[[@B8],[@B9]\]. The positionally cloned \[[@B10]\] candidate for these 3 genes was designated as the natural resistance associated macrophage protein 1 (*Nramp1*) for a period before its specific function as a transporter was confirmed \[[@B11]\]. In mice, susceptibility to infection is associated with a coding region mutation in transmembrane domain 4 of *Slc11a1*\[[@B10]\]. In humans, no functional coding region variants have been identified \[[@B12]\], but common alleles 2 \[T(GT)~5~AC(GT)~5~AC(GT)~10~\] and 3 \[T(GT)~5~AC(GT)~5~AC(GT)~9~\] of a functional \[[@B13]\] Z-DNA forming GT~n~repeat (rs34448891) in the promoter region have been associated with disease risk, or protection from, a number of autoimmune and infectious diseases (reviewed \[[@B8],[@B14]\]). Amongst these associations, a common theme was risk of autoimmune disease with allele 3 which drives higher SLC11A1 expression and pro-inflammatory cytokine production by macrophages, while the lower expressing allele 2 was associated with anti-inflammatory cytokines and infectious disease susceptibility, including tuberculosis \[[@B15]\]. In contrast, in Sudan the proinflammatory GT~n~repeat allele 3 is on a risk haplotype for VL caused by *L. donovani*that includes variants at single nucleotide polymorphisms (SNPs) designated 274C/T in exon 3 (rs2276631) and 469 + 14G/C in intron 4 (rs3731865) in the 5\' region of the gene \[[@B12]\]. This was interpreted in relation to VL pathology which is associated with a strong pro-inflammatory tumour necrosis factor alpha response \[[@B16]\]. In some populations infectious disease association (listed in additional on-line tables in reference \[[@B17]\]) has been with 3\' variants at *SLC11A1*rather than, or in addition to, the 5\' polymorphic loci, including two insertion/deletion (IN/DEL) polymorphisms TGTG/- (rs17235416) and CAAA/- (rs17229009) in the 3\'UTR. The latter are potentially regulatory polymorphisms, although this has not been demonstrated experimentally. Here we report on well-powered two-stage primary family-based, followed by a replication population-based, genetic association study that fails to support either a role for polymorphism at *SLC11A1*in determining susceptibility to VL caused by *L. donovani*in India, or for the GT~n~repeat polymorphism in determining mRNA expression levels of SLC11A1 in splenic aspirates from VL patients before or after chemotherapy.

Methods
=======

The study was conducted in the district of Muzaffarpur in Bihar State, India, where VL is highly endemic. VL cases and family members or controls were from villages located within a radius of \~100 km from the city of Muzaffarpur covering the districts of Muzaffarpur, Vaishali, Samastipur, Saran, Sheohar, East Champaran and Sitamarhi. Initially, families with at least two siblings affected with clinical VL were ascertained from medical records held in the Kala-Azar Medical Research Centre (KAMRC) in Muzaffarpur, India \[[@B18]\]. This was later extended to collection of singleton cases plus parent (trios) (see Table [1A](#T1){ref-type="table"}). The replication study comprised 958 unrelated cases and 1015 unrelated controls. The controls had no history of VL, or a family history of VL among first-, second- or third-degree relatives. Patients and controls were matched for self-reported age, sex, religion, caste and geographic district of recruitment (see Table [1B](#T1){ref-type="table"}). Diagnosis of VL was based on presence of typical clinical features of VL i.e. fever with rigors and chills, splenomegaly, weight loss and pancytopenia followed by demonstration of parasites by parasitological methods (light microscopy, *in vitro*culture) using splenic aspirates \[[@B19]\]. Additional VL cases identified in the field were confirmed on the basis of proof of medical records of diagnosis and treatment issued from one of the local health clinics or private practice, and accompanied by demonstration of clinical response to anti-leishmanial treatment (typically with amphotericin B). An annual incidence rate of 2.49 clinical VL cases/1,000 persons has been reported in the region \[[@B20]\]. *L. donovani sensu strictu*(zymodeme MON-2) was confirmed as the causative agent of VL in the study region, in accordance with other reports on clinical isolates from kala-azar patients in the state of Bihar \[[@B21]-[@B24]\]. Additional epidemiological and demographic details relating to the study site are described elsewhere \[[@B25]\]. Informed written consent in Hindi was obtained from all participating individuals and from parents of children under 18 years old. Approval for the study was provided by the Ethical Committee of the Institute of Medical Sciences, Banaras Hindu University, Varanasi, India. Collection of families for the primary study was undertaken between 2004 and 2006. The replication study collection was undertaken during 2009-2010. For the family-based primary study DNA was prepared from buccal swabs by whole genome amplification as described \[[@B18]\], and SNPs genotyped using ABI predesigned Taqman assays (ABI, Mulgrave, Victoria, Australia). For the replication case-control study, genomic DNA was extracted from saliva using the Oragene technology (DNA Genotek, Ontario, Canada), and SNPs genotyped using Sequenom iPLEX platform (Sequenom, San Diego, CA). The GT~n~repeat and IN/DELS were genotyped for all samples using ABI fragment analysis processed on an ABI3130 (Australia) or ABI3730 (India) Genetic Analyser.

###### 

Baseline characteristics of (A) families for the primary sample of Indian multicase VL families, and (B) the Indian case-control cohorts.

  \(A\) Family Structure                  Number\*
  --------------------------------------- ------------
  N° families                             137
                                          
  N° nuclear families                     176
                                          
  Nuclear families with 1 affected sib    63
                                          
  Nuclear families with 2 affected sibs   95
                                          
  Nuclear families with 3 affected sibs   14
                                          
  Nuclear families with 4 affected sibs   2
                                          
  Nuclear families with 5 affected sibs   2
                                          
  N° affected offspring                   313
                                          
  N° affected parents                     63
                                          
  Total N° affected individuals           394
                                          
  Total N° individuals                    836
                                          
  **(B) Case-Control Sample**             **Number**
                                          
  **Cases (no.)**                         958
                                          
  Male                                    571
                                          
  Female                                  387
                                          
  Mean age at study encounter ±SD (yr)    31.2 ±16.7
                                          
  Range                                   3-73
                                          
  Mean age at onset of VL ±SD (yr)        26.8 ±15.3
                                          
  Religious Group (no.)                   
   Hindu                                  850
   Muslim                                 108
                                          
  **Controls (no.)**                      1015
                                          
  Male                                    570
                                          
  Female                                  445
                                          
  Mean age at study encounter ±SD (yr)    31.8 ±15.9
                                          
  Religious Group (no.)                   
   Hindu                                  885
   Muslim                                 130

\* Numbers are given for the individuals with DNA available for genotyping

Family-based allelic association tests based on the TDT but generalized to allow analysis under additive and genotype-wise models of inheritance were performed within FBAT under the null hypothesis of \"no linkage and no association\" \[[@B26],[@B27]\]. TDT power approximations \[[@B28]\] show that the 313 primary VL trios had ≥95% power to detect an odds ratio ≥2 at *P*= 0.01 for markers with MAF ≥ 0.1, but only 49% power for an odds ratio of 1.5. Nevertheless, our primary sample was well-powered to detect effect sizes (odds ratios ≥ 2) equivalent to those observed in the earlier study of *SLC11A1*and VL in Sudan \[[@B12]\]. Robust association tests were performed to take account of multiple trios within a pedigree. Association tests for the replication case-control sample were undertaken using logistic regression analysis performed in PLINK \[[@B29]\] or LOGIT (Stata) using an additive model and a genotypic test. The 941 cases and 992 controls which passed quality control (Hardy-Weinberg Equilibrium) had 100% power to detect associations with an odds ratio of 2 for markers with MAF ≥ 0.1 at *P*= 0.001, and 93.5% power for odds ratio 1.5; MAF ≥ 0.1, *P*= 0.01.

Splenic biopsies were taken as part of routine diagnostic procedure at the Kala Azar Medical Research Centre, Muzaffarpur, Bihar State, India. Since the spleen is a major focus for parasite growth inside macrophages, this afforded an important opportunity to analyse gene expression in a primary site of infection. Pre- and post- treated patient\'s splenic samples were collected in 5 × RNA Later (Ambion) during 2009-2010, transported to Varanasi at 4°C and stored at -80°C until RNA was isolated. Details regarding age and sex (15 males, median age 16, range 7 to 45 years; 9 females, median age 10, range 8 to 30 years) splenic parasites (21 confirmed positive; 3 not done) and drug administered (19 Miltefosine; 1 Miltefosine + Paramomycin; 1Ambisome + Paramomycin; 3Amphomul) were recorded for each patient. Total RNA was isolated using RNeasy tissue kit (Qiagen) according to the manufacturer\'s instructions and eluted in 30 ul of RNase free water. Sample quality and integrity was assessed by ND-2000 spectrophotometer (Thermo Fischer Scientific) and agarose (Sigma Aldrich) gel electrophoresis. 500 ng of RNA was reverse transcribed using the High Capacity cDNA synthesis kit (Applied Biosystems). Taqman predesigned gene expression assay (Hs00184453_m1) was used to perform expression studies (7500 HT Real Time PCR system, ABI, Foster City CA, USA) with 18S rRNA (P/N 4319413E) used as an endogenous control to normalize the expression data. Experiments were performed on 24 paired pre- and post-treatment splenic aspirates from VL patients with appropriate no RT and no template controls included in each plate. All samples were run in duplicate. Results were analysed by 7500 software v.2.0.1 and Graph pad prism 5. Paired Student\'s T tests was used to test for significant differences between pre (Day-0) and post (D-30) expression levels for each genotype, i.e. 3/3, 3/2 and 2/2. One way ANOVA was used to test for differences between 3/3 vs 3/2 vs 2/2 groups at either Day-0 or Day-30.

Results and Discussion
======================

To undertake our study we initially genotyped 9 polymorphisms (Table [2](#T2){ref-type="table"}) in 176 nuclear families (Table [1](#T1){ref-type="table"}) used in our previous study \[[@B18]\] that contain 313 offspring with VL collected in the area of Muzaffarpur, Bihar State, India, where *L. donovani*is endemic. This included the putative functional 5\' GT~n~repeat and 3\'UTR TGTG/- and CAAA/- IN/DELs, as well as the exon 3 274C/T (rs2276631) and intron 4 469 + 14G/C (rs3731865) SNPs shown to be associated with VL in Sudan \[[@B12]\]. Using the family-based association test (FBAT) \[[@B30],[@B31]\] in this primary family dataset (Table [3](#T3){ref-type="table"}) we found tentative evidence (nominal *P*-values ≤0.05) for associations between VL and 5\' GT~n~repeat, and between VL and the 3\'UTR CAAA/- IN/DEL. In particular (Table [3B](#T3){ref-type="table"}), homozygosity for the high expressing pro-inflammatory allele 3 at the GT~n~repeat was associated with disease (Z-score = +2.382; nominal *P*= 0.017), while homozygosity for allele 2 (the deletion) was associated with protection for the 3\'UTR CAAA IN/DEL (Z-score = -2.332; nominal *P*= 0.019). Since these two markers are not in strong LD with each other (Additional Figure [1](#F1){ref-type="fig"}: D\' = 0.52; r2 = 0.16), these associations are likely to be independent, if real. Neither association is robust to application of a strict Bonferroni correction for 9 SNPs genotyped, which requires a significance cut-off of *P*≤ 0.006 (i.e. *P*= 0.05/9). Given that the 8 SNPs that passed quality control are not all independent (Additional Figure [1](#F1){ref-type="fig"}), this is over-conservative. A less stringent correction taking account of non-independence of markers provides a cut-off of *P*≤ 0.017 (i.e. *P*= 0.05/3; 2 LD blocks plus 1 independent marker).

###### 

Details of polymorphisms genotyped and the minor allele frequency (MAF) of variants in the Indian study population.

  Common Designation        Location    Amino Acid Change   SNP Identity   **Physical Position**^**1**^**(bp)**   **Alleles**^**2**^   MAF
  ------------------------- ----------- ------------------- -------------- -------------------------------------- -------------------- -------
  GTn                       5\'UTR                          rs34448891     218954900                              118/120^4^           0.190
                                                                                                                                       
  -237C/T                   5\'UTR                          rs7573065      218954951                              C/T                  0.068
                                                                                                                                       
  274C/T^3^                 Exon 3      F66F                rs2276631      218957257                              G/A                  0.141
                                                                                                                                       
  469 + 14G/C^3^            Intron 4                        rs3731865      218958247                              C/G                  0.142
                                                                                                                                       
  823 C/T^3^                Exon 8      G249G               rs17221959     218960874                              C/T                  0.193
                                                                                                                                       
  1465-85G/A^3^             Intron 13                       rs2279015      218967514                              C/T                  0.323
                                                                                                                                       
  D543N G/A^3^              Exon 15     D543N               rs17235409     218967976                              G/A                  0.073
                                                                                                                                       
  1729 + 55del4^3^(TGTG)    3\'UTR                          rs17235416     218968058                              IN/DEL               0.067
                                                                                                                                       
  1729 + 263del4^3^(CAAA)   3\'UTR                          rs17229009     218968275                              DEL/IN               0.287

^1^Physical positions of markers are given according to Build 36.3 of the human genome; ^2^Major \> minor alleles for this Indian population; ^3^bp positions of variants relative to an arbitrary site 76bp upstream \[[@B33]\] of the methionine start codon; ^4^allele 3/allele 2 (alleles 1 and 4 were rare or absent from this population).

###### 

Family-based association analysis between *SLC11A1*and VL

  \(A\) Additive model                                                                                                        
  ----------------------------- -------------- ------------------------ ------------ ------- ---------- ------------ -------- -----------
  **Common Designation**        **Allele**     **Allele frequency**     **\# Fam**   **S**   **E(S)**   **Var(S)**   **Z**    ***P***
                                                                                                                              
  **GT**~**n**~                 2              0.15                     68           60      70.38      28.4         -1.947   **0.052**
                                                                                                                              
                                3              0.85                     68           176     165.62     28.4         1.947    **0.052**
                                                                                                                              
  **274C/T**                    1              0.88                     43           104     99.65      16.3         1.076    0.282
                                                                                                                              
                                2              0.12                     43           36      40.35      16.3         -1.076   0.282
                                                                                                                              
  **469 + 14G/C**               1              0.11                     20           17      21.50      9.7          -1.445   0.148
                                                                                                                              
                                2              0.89                     20           61      56.50      9.7          1.445    0.148
                                                                                                                              
  **823 C/T**                   1              0.92                     46           127     121.97     20           1.127    0.260
                                                                                                                              
                                2              0.08                     46           41      46.03      20           -1.127   0.260
                                                                                                                              
  **1465-85G/A**                1              0.31                     92           117     119.63     42.9         -0.402   0.688
                                                                                                                              
                                2              0.69                     92           229     226.37     42.9         0.402    0.688
                                                                                                                              
  **1729 + 55del4 (TGTG)**      1              0.05                     19           18      21.50      9.57         -1.131   0.258
                                                                                                                              
                                2              0.95                     19           54      50.50      9.57         1.131    0.258
                                                                                                                              
  **1729 + 263del4 (CAAA)**     1              0.74                     88           216     203.33     41.2         1.974    **0.048**
                                                                                                                              
                                2              0.26                     88           104     116.67     41.2         -1.974   **0.048**
                                                                                                                              
  **(B) Genotype-wise model**                                                                                                 
                                                                                                                              
  **Common Designation**        **Genotype**   **Genotype frequency**   **\# Fam**   **S**   **E(S)**   **Var(S)**   **Z**    ***P***
                                                                                                                              
  **GT**~**n**~                 2\\2           0.025                    9            8       6.69       2.9          0.759    0.447
                                                                                                                              
                                2\\3           0.250                    68           44      57.00      25.7         -2.565   **0.010**
                                                                                                                              
                                3\\3           0.725                    65           66      54.31      24.1         2.382    **0.017**
                                                                                                                              
  **1729 + 263del4 (CAAA)**     1\\1           0.566                    75           69      63.57      27.9         1.027    0.304
                                                                                                                              
                                1\\2           0.347                    87           78      76.19      33.9         0.311    0.755
                                                                                                                              
                                2\\2           0.087                    26           13      20.24      9.64         -2.332   **0.019**

FBAT analysis under (A) additive and (B) genotype-wise models of inheritance for associations between *SLC11A1*polymorphisms and the primary family-based sample of VL from Bihar State, India. \# Fam = number of families informative for the FBAT analysis; S and E(S) represent the observed and expected transmissions for that allele, Var(S) is the variance. A positive Z score indicates association with disease; a negative Z score indicates the non-associated or protective allele or genotype. Bold indicates significant associations at nominal *P*≤ 0.05. The corrected *P*-value required to achieve significance taking account of multiple but not independent markers is *P*≤ 0.017. Results are shown for the 7 polymorphisms that were genotyped in the primary family-based sample. All passed HWE (*P*-value cut-off 0.05/7 = 0.07 for 7 markers genotyped) in unaffected family founders.

Suggestive evidence for an association between Indian VL and allele 3 at the functional promoter region GT~n~polymorphism at *SLC11A1*, which was consistent with data for VL from Sudan \[[@B12]\], prompted us to pursue two further avenues of investigation. First, we looked at expression levels of *SLC11A1*in mRNA from splenic aspirates from patients carrying the 3 different genotypes at the GT~n~repeat (Figure [1](#F1){ref-type="fig"}). This failed to show any significant differences in expression levels of SLC11A1 in splenic aspirates from VL patients carrying the three GT~n~genotypes, either before or after treatment, as determined using one way ANOVA. Nor were there differences in expression within each genotype when pre- and post-treatment values were compared using paired Student\'s T tests. This suggests that differences in expression levels driven by the GT~n~repeat in luciferase assays *in vitro*, especially under lipopolysaccharide and interferon-γ stimulation \[[@B13],[@B32]\], do not necessarily translate into regulation of expression in VL infected spleens *in vivo*. Secondly, we carried out a comprehensive replication of the association study in a much larger population-based case-control sample from the same region of Bihar State in India (Table [4](#T4){ref-type="table"}). This study failed to show association between VL and any of the 8 markers that passed quality control. The trend for genotypic association at the GT~n~was in the reverse direction (i.e. a3 was the risk allele in the primary sample, and the protective allele in the replication samples) to that seen in the primary analysis (Table [3](#T3){ref-type="table"}). Analyses using caste, which we have shown to provide a good surrogate for population substructure in genome-wide analyses (unpublished data), or religion as covariates also failed to provide evidence for positive associations in the case-control analysis (data not shown).

###### 

Population-based association analysis between *SLC11A1*and VL

  \(A\) Logistic regression test under additive model                                                                                      
  ----------------------------------------------------------- --------------- -------------- ---------------- -------- --------- --------- ---------
  **Common Designation**                                      **Allele**      **Affected**   **Unaffected**   **OR**   **L95**   **U95**   ***P***
                                                                                                                                           
  GT~n~                                                       2               355/1473       353/1533         1.05     0.89      1.23      0.585
                                                                                                                                           
  -237C/T                                                     2               135/1747       122/1862         1.18     0.91      1.52      0.205
                                                                                                                                           
  274C/T                                                      2               258/1624       286/1698         1.06     0.88      1.27      0.529
                                                                                                                                           
  469 + 14G/C                                                 1               266/1582       274/1632         1.00     0.83      1.19      0.987
                                                                                                                                           
  1465-85G/A                                                  1               605/1263       646/1308         1.03     0.90      1.18      0.664
                                                                                                                                           
  D543N G/A                                                   2               145/1735       112/1526         0.88     0.68      1.14      0.313
                                                                                                                                           
  1729 + 55del4 (TGTG)                                        1               110/1488       112/1608         1.06     0.81      1.39      0.669
                                                                                                                                           
  1729 + 263del4 (CAAA)                                       2               437/1123       515/1233         0.93     0.80      1.08      0.364
                                                                                                                                           
  **(B) Genotypic-wise logistic regression analysis (2df)**                                                                                
                                                                                                                                           
  **Common Designation**                                      **Genotypes**   **Cases**      **Controls**     **OR**   ***P***             
                                                                                                                                           
  GT~n~                                                       2/2             40             27               1        \-                  
                                                                                                                                           
                                                              2/3             275            299              0.62     0.070               
                                                                                                                                           
                                                              3/3             599            617              0.66     0.098               
                                                                                                                                           
  1729 + 263del4 (CAAA)                                       2/2             67             79               1        \-                  
                                                                                                                                           
                                                              1/2             303            357              0.91     0.346               
                                                                                                                                           
                                                              1/1             410            438              0.90     0.583               

Logistic regression analyses under (A) an additive model and (B) using a genotypic (2 df) test for the replication sample of VL cases and controls from Bihar State, India OR = odds ratio (for minor allele relative to major allele in part A); L95 and U95 are lower and upper 95% confidence intervals. In (A) allele counts are shown for mino/major allele for affected and unaffected individuals. There were no significant associations at nominal *P*≤ 0.05. The corrected *P*-value required to achieve significance taking account of multiple but not independent markers is *P*≤ 0.017. Data are shown for all markers that were in HWE (*P*-value cut-off 0.05/9 = 0.006 for 9 markers genotyped) in the control sample. Marker 823C/T failed HWE quality control. Markers D543N G/A (0.1% cases versus 17% controls) and 1729 + 263del4 (CAAA) (17% cases versus 10.7% controls) showed differential missingness between cases and controls, which can be a concern for its potential to generate false positive results \[[@B34]\].

![**Relative expression of SLC11A1 mRNA in splenic aspirates from VL patients (A) before (Day 0), and (B) after (Day 30), antileishmanial treatment**. Data are shown according to genotype (3/3, 2/3, 2/2) at the *SLC11A1*GT~n~promoter repeat polymorphism. Values represent mean ± SEM. Paired Student\'s T test showed no significant differences in expression of SLC11A1 when D0 values were compared to D30 valules for each genotype. No differences between genotypes were observed at either D0 or D30 as deteremined by one way ANOVA.](1471-2350-12-71-1){#F1}

Here we re-examined *SLC11A1*as a candidate gene for susceptibility to VL in India. Despite preliminary evidence for a role for putative functional polymorphisms in the 5\' promoter and 3\'UTR regions, we were unable to find supporting evidence for this in functional studies or in a large, well-powered, replication sample for association analysis. We conclude that *SLC11A1*does not play a major role in determining susceptibility to VL in India. These results also call into question the earlier association observed between VL and SLC11A1 in Sudan \[[@B12]\], which was based on a single small sample of families. Whilst this could represent genetic heterogeneity between human populations and/or the parasite, it is also possible that this first report of association in humans could be a case of beginner\'s curse. Results presented here suggest that associations observed in small-scale primary samples require validation to determine whether they remain true for the population in which they have been observed.

Conclusions
===========

This is the first well-powered study of *SLC11A1*as a candidate for VL, which we conclude does have a major role in regulating VL susceptibility in India.
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###### Additional File 1

**Figure S1**. Haploview analysis for D\' and r^2^pairwise measures of linkage disequilibrium between *SLC11A1*polymorphisms in the control sample for the replication sample from India.
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